BridgeBio Oncology Therapeutics Inc.
NASDAQ: BBOT0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Eli Wallace
- Employees
- 62
- Headquarters
- South San Francisco, United States
- IPO year
- 2025
- Market cap
- $596.0M
- Website
- https://bbotx.com
Loading BBOT…
Loading profile data…Frequently asked questions about BBOT
What does BridgeBio Oncology Therapeutics Inc. (BBOT) do?
BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical firm dedicated to pioneering advanced small molecule treatments. These therapies are aimed at combating malignancies driven by RAS and PI3Kα, both frequently encountered oncogenes in human cancers. Initially established as an offshoot of BridgeBio Pharma, the company...
Where does BBOT trade?
BridgeBio Oncology Therapeutics Inc. (BBOT) trades on the NASDAQ Global Market.
What sector is BBOT in?
BridgeBio Oncology Therapeutics Inc. (BBOT) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of BridgeBio Oncology Therapeutics Inc.?
Eli Wallace is the chief executive officer of BridgeBio Oncology Therapeutics Inc. (BBOT).
Where is BridgeBio Oncology Therapeutics Inc. headquartered?
BridgeBio Oncology Therapeutics Inc. is headquartered in United States.
Does BBOT pay a dividend?
BridgeBio Oncology Therapeutics Inc. (BBOT) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BBOT go public?
BridgeBio Oncology Therapeutics Inc. (BBOT) completed its initial public offering in 2025.